Medipharm Labs Corp
TSX:LABS

Watchlist Manager
Medipharm Labs Corp Logo
Medipharm Labs Corp
TSX:LABS
Watchlist
Price: 0.07 CAD
Market Cap: 29.5m CAD

Medipharm Labs Corp
Total Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Medipharm Labs Corp
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Medipharm Labs Corp
TSX:LABS
Total Receivables
CA$7.7m
CAGR 3-Years
-17%
CAGR 5-Years
-24%
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Total Receivables
$2.4B
CAGR 3-Years
12%
CAGR 5-Years
7%
CAGR 10-Years
-1%
Canopy Growth Corp
TSX:WEED
Total Receivables
CA$26.9m
CAGR 3-Years
-37%
CAGR 5-Years
-20%
CAGR 10-Years
31%
Sundial Growers Inc
NASDAQ:SNDL
Total Receivables
CA$26.3m
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Total Receivables
$38.2m
CAGR 3-Years
7%
CAGR 5-Years
9%
CAGR 10-Years
54%
K
Knight Therapeutics Inc
TSX:GUD
Total Receivables
CA$130.1m
CAGR 3-Years
12%
CAGR 5-Years
13%
CAGR 10-Years
53%
No Stocks Found

Medipharm Labs Corp
Glance View

Market Cap
29.5m CAD
Industry
Pharmaceuticals

MediPharm Labs Corp. is medicinal cannabis company, which engages in the pharmaceutical grade production of cannabis oil products. The company is headquartered in Barrie, Ontario and currently employs 190 full-time employees. The company went IPO on 2018-02-09. The firm produces purified, pharmaceutical-like cannabis extracts and related derivative products. The firm formulates, processes, packages and distributes cannabis extracts and cannabinoid-based products at its Canadian and Australian facilities for domestic and international markets. The Company, through its subsidiaries is engaged in the sale and distribution of cannabis oil, cannabis extracts, cannabis edibles, cannabis topicals, and derivatives to authorized classes of purchasers, as well as controlled human administration trials for sensory testing of cannabis extracts and derivative products. The company is also engaged in the manufacturing of extracts and tinctures of cannabis and cannabis resin for the purpose of a clinical trial or prescribed as medical cannabis products. The firm's wholly owned subsidiaries include MediPharm Labs Inc. and MediPharm Labs Australia Pty. Ltd.

LABS Intrinsic Value
0.11 CAD
Undervaluation 39%
Intrinsic Value
Price

See Also

What is Medipharm Labs Corp's Total Receivables?
Total Receivables
7.7m CAD

Based on the financial report for Sep 30, 2025, Medipharm Labs Corp's Total Receivables amounts to 7.7m CAD.

What is Medipharm Labs Corp's Total Receivables growth rate?
Total Receivables CAGR 5Y
-24%

Over the last year, the Total Receivables growth was 15%. The average annual Total Receivables growth rates for Medipharm Labs Corp have been -17% over the past three years , -24% over the past five years .

Back to Top